Facebook tracking pixel

Coming Soon

S10.AI's Next-Generation Telehealth Platform

K31.7
ICD-10-CM
Brunner's Gland Hyperplasia

Learn about Brunner's Gland Hyperplasia, also known as Brunner's gland adenoma or duodenal gland hyperplasia. This resource provides information on diagnosis, clinical documentation, and medical coding for Brunner's Gland Hyperplasia. Find details relevant to healthcare professionals, including ICD-10 codes and best practices for documenting this duodenal condition in patient records. Understand the key differences between Brunner's Gland Hyperplasia and other duodenal pathologies for accurate clinical documentation and medical coding.

Also known as

Brunner's gland adenoma
Duodenal gland hyperplasia

Diagnosis Snapshot

Key Facts
  • Definition : Overgrowth of Brunner's glands in the duodenum (first part of small intestine).
  • Clinical Signs : Often asymptomatic. Can cause upper GI bleeding, abdominal pain, nausea, and rarely, obstruction.
  • Common Settings : Detected incidentally during endoscopy or imaging for other GI issues.

Related ICD-10 Code Ranges

Complete code families applicable to AAPC K31.7 Coding
K20-K31

Diseases of esophagus, stomach and duodenum

Covers various disorders affecting the esophagus, stomach, and duodenum, including hyperplasia.

D13.1

Benign neoplasm of duodenum

Specifically designates benign tumors (including adenomas) within the duodenum.

K92.8

Other specified diseases of intestines

A general category for intestinal diseases not classified elsewhere, potentially including hyperplasia.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is Brunner's gland hyperplasia confirmed?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Excess Brunner's gland tissue in duodenum.
Benign Brunner's gland tumor in duodenum.
Duodenal inflammation near Brunner's glands.

Documentation Best Practices

Documentation Checklist
  • Document duodenal location and extent.
  • Describe endoscopic findings (size, number, appearance).
  • Histopathology report confirming Brunner's gland hyperplasia.
  • Rule out other duodenal pathologies.
  • ICD-10-CM code K31.8 for documentation and billing.

Coding and Audit Risks

Common Risks
  • Unspecified Location

    Coding Brunner's gland hyperplasia requires specifying duodenum or other location. Unspecified site leads to coding errors and claim rejections.

  • Atypical Hyperplasia

    Distinguishing Brunner's gland hyperplasia from atypical hyperplasia or neoplasia is crucial for accurate coding and treatment planning. Misdiagnosis impacts patient care and reimbursement.

  • Clinical Validation

    Coding based on clinical findings, not just pathology reports, ensures accurate code assignment for Brunner's gland hyperplasia. Insufficient documentation can lead to audits and denials.

Mitigation Tips

Best Practices
  • Document duodenal location, size, and number of Brunner's gland lesions for ICD-10-CM K31.8
  • Code K31.8 for Brunner's gland hyperplasia, adenoma, or duodenal gland hyperplasia
  • Correlate endoscopic findings with histology for Brunner's gland hyperplasia diagnosis
  • Distinguish Brunner's gland hyperplasia from other duodenal lesions in documentation
  • For symptomatic cases, link Brunner's gland hyperplasia to symptoms in clinical notes

Clinical Decision Support

Checklist
  • Confirm duodenal location of lesion via endoscopy/imaging.
  • Histopathology report confirms Brunner's gland hyperplasia.
  • Exclude other duodenal pathologies (e.g., adenoma, carcinoma).
  • Assess for symptoms like GI bleeding, obstruction, or abdominal pain.

Reimbursement and Quality Metrics

Impact Summary
  • Brunner's Gland Hyperplasia: Coding, Billing, Reimbursement, Quality Metrics Impact Summary
  • ICD-10 K31.8 impacts MS-DRG assignment and potential case mix index.
  • Accurate endoscopic biopsy coding (CPT 88305) crucial for appropriate reimbursement.
  • Timely pathology reporting affects hospital efficiency and quality metrics.
  • Duodenal gland hyperplasia diagnosis may influence quality indicators for GI complications.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Frequently Asked Questions

Common Questions and Answers

Q: What are the key endoscopic and histologic features that differentiate Brunner's Gland Hyperplasia from other duodenal lesions like Brunner's gland adenoma or a duodenal carcinoid?

A: Differentiating Brunner's Gland Hyperplasia (BGH) from other duodenal lesions requires careful endoscopic and histologic evaluation. Endoscopically, BGH typically presents as multiple, small, sessile or pedunculated nodules in the duodenal bulb, often appearing as a cobblestone or grape-like cluster. Brunner's gland adenomas are usually solitary and larger. Duodenal carcinoids can also appear as nodules but may exhibit central umbilication or ulceration. Histologically, BGH demonstrates diffuse proliferation of Brunner's glands without architectural distortion, while adenomas show localized, encapsulated glandular growth with some architectural distortion. Carcinoids exhibit characteristic neuroendocrine features with uniform cells arranged in nests or trabeculae. Immunohistochemical stains can be helpful in challenging cases. Explore how these features aid in accurate diagnosis and guide appropriate management strategies.

Q: When is endoscopic resection indicated for Brunner's Gland Hyperplasia, and what are the preferred techniques (e.g., snare polypectomy, endoscopic mucosal resection, etc.) considering potential complications like bleeding or perforation?

A: While Brunner's Gland Hyperplasia (BGH) is often asymptomatic and doesn't require intervention, endoscopic resection is indicated when symptoms like duodenal obstruction, bleeding, or persistent abdominal pain arise. Additionally, large or suspicious lesions warrant resection to exclude malignancy or Brunner's gland adenoma. Preferred endoscopic techniques include snare polypectomy for smaller, pedunculated lesions and endoscopic mucosal resection (EMR) for larger, sessile lesions. Endoscopic submucosal dissection (ESD) may be considered for complex cases. Potential complications like bleeding and perforation are rare but possible. Careful consideration of lesion size, location, and morphology is crucial in selecting the appropriate technique and minimizing risks. Consider implementing a standardized endoscopic approach to enhance patient safety and optimize outcomes. Learn more about the latest advancements in endoscopic resection techniques for duodenal lesions.

Quick Tips

Practical Coding Tips
  • Code K86.1 for Brunner's Gland Hyperplasia
  • Check documentation for adenoma vs hyperplasia
  • Duodenal gland hyperplasia, same code K86.1
  • Consider D13.7 if uncertain, document clearly
  • Rule out neoplasm, review pathology report

Documentation Templates

Patient presents with symptoms suggestive of Brunner's Gland Hyperplasia, including  abdominal pain, dyspepsia, and nausea.  Differential diagnosis includes peptic ulcer disease, gastritis, and duodenal adenoma.  Physical examination was unremarkable.  Upper endoscopy revealed prominent submucosal nodules in the duodenum, consistent with Brunner's gland hyperplasia or Brunner's gland adenoma. Biopsies were taken and sent for histopathological analysis to confirm the diagnosis and rule out malignancy.  The patient's symptoms, endoscopic findings, and potential for complications like gastrointestinal bleeding or obstruction warrant further investigation.  Preliminary diagnosis of duodenal gland hyperplasia is considered.  Treatment options, including medical management with proton pump inhibitors or H2 blockers for symptom control and surgical resection for larger or symptomatic lesions, will be discussed upon receiving pathology results. ICD-10 code D13.7 is tentatively assigned, pending histopathologic confirmation. CPT codes for the endoscopic procedure and biopsy, such as 43239 and 43235 respectively, are also documented. This assessment will be updated following the review of the biopsy findings and correlation with the patient's clinical presentation.